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Therapeutic targeting of tumor angiogenesis with
VEGF inhibitors results in demonstrable, but transi-
tory efficacy in certain human tumors and mouse
models of cancer, limited by unconventional forms
of adaptive/evasive resistance. In one such mouse
model, potent angiogenesis inhibitors elicit com-
partmental reorganization of cancer cells around re-
maining blood vessels. The glucose and lactate
transporters GLUT1 and MCT4 are induced in distal
hypoxic cells in a HIF1a-dependent fashion, indica-
tive of glycolysis. Tumor cells proximal to blood ves-
sels instead express the lactate transporter MCT1,
and p-S6, the latter reflecting mTOR signaling. Nor-
moxic cancer cells import and metabolize lactate,
resulting in upregulation of mTOR signaling via gluta-
mine metabolism enhanced by lactate catabolism.
Thus, metabolic symbiosis is established in the
face of angiogenesis inhibition, whereby hypoxic
cancer cells import glucose and export lactate, while
normoxic cells import and catabolize lactate. mTOR
signaling inhibition disrupts this metabolic symbio-
sis, associated with upregulation of the glucose
transporter GLUT2.INTRODUCTION
Judah Folkman’s vision of targeting the tumor neovasculature as
a new modality of cancer therapeutics has inspired a series of
drugs that either exclusively (e.g., bevacizumab) or primarily
(e.g., sunitinib, axitinib, and sorafenib) inhibit VEGF signaling
(McIntyre and Harris, 2015; Vasudev and Reynolds, 2014; and
references therein) with associated beneficial responses, repre-
senting proof of principle and new additions to the armamen-
tarium of anti-cancer drugs. However, as with many targeted1144 Cell Reports 15, 1144–1160, May 10, 2016 ª 2016 The Authors
This is an open access article under the CC BY license (http://creativetherapies, clinical responses to angiogenesis inhibitors (AI) are
typically limited, manifested as increased, but limited progres-
sion-free survival and variable (or no) overall survival (Vasudev
and Reynolds, 2014; and references therein). Concurrent with
such clinical investigations, a number of preclinical studies of
AI in various mousemodels of human cancer have revealed mul-
tiple forms of adaptive resistance that enable tumors to evade
the effects of AI therapy (Bergers and Hanahan, 2008; Clarke
and Hurwitz, 2013; Welti et al., 2013; McIntyre and Harris,
2015; Rigamonti et al., 2014; Rivera et al., 2015). One such
model—RIP1Tag2 transgenic mice, which develop de novo
pancreatic neuroendocrine tumors (PanNET) via a multistage
pathway—has been particularly instructive: tumorigenesis in-
volves a discrete angiogenic switch (Folkman et al., 1989), which
is necessary for initial tumor formation. AIs, in particular ones tar-
geting the VEGF signaling pathway, show demonstrable efficacy
in this model (Bergers et al., 2003), the results of whichmotivated
clinical trials that led to the approval of one such agent, sunitinib,
in human PanNET (Raymond et al., 2011). Importantly, however,
AIs are not curative in this mouse model, much as in human can-
cer patients. The basis for treatment failure lies in part in the
development of multiple forms of adaptive resistance to AIs,
including revascularization mediated by alternative pro-angio-
genic signaling circuits (Casanovas et al., 2005), recruitment of
vascular-protective myeloid cells (Shojaei and Ferrara, 2008),
and cooption of normal tissue vessels via increased invasion
and metastasis (Sennino et al., 2012; Ebos and Kerbel, 2011;
Ebos et al., 2009; Pa`ez-Ribes et al., 2009).
The RIP1Tag2 model has also been used to investigate other
cancer hallmarks, including resistance to apoptosis and induc-
tion of invasiveness, which are variously regulated by signaling
from receptor tyrosine kinases, including EGFR, IGFR, IR, and
ALK (Chun et al., 2010; Nolan-Stevaux et al., 2010; Ulanet
et al., 2010); these signals converge in part on the mTOR kinase,
which orchestrates a broad program affecting cell survival and
metabolism (Laplante and Sabatini, 2012; Cornu et al., 2013).
Notably, both preclinical (Chiu et al., 2010) and clinical studies
(Yao et al., 2011) have demonstrated the efficacy of targeting
mTOR in PanNET.commons.org/licenses/by/4.0/).
Figure 1. Effects of Potent Angiogenesis Inhibition on mTOR Signaling; Upregulation and Relocalization into Focal Clusters
(A) Quantitation of p-S6 intensity in western blots (WB) of tumors treated with sunitinib versus sham control (top left). All samples were first normalized using a
Bradford assay and aWB for actin. The blots were probed with p-S6 antibodies, and the relative values of Mono-S- (n = 8, red) treated tumors were compared to
controls (blue, n = 7) by quantitation using the Fusion FX7 imaging system (see Supplemental Information). A similar trendwas seen for tumors treatedwith axitinib
(data not shown). The protein lysates were prepared from PanNET tumors collected from RIP1Tag2 mice, following a 1-week trial from 14–15 weeks of age. The
(legend continued on next page)
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We have continued to assess the effects on AI therapy in this
PanNETmodel, including a comparative analysis of twomulti-ki-
nase inhibitors, sunitinib and axitinib, both of which target the
VEGFR/PDGFR signaling pathways to inhibit new blood vessel
growth and disrupt endothelial cells and pericytes of the preex-
isting tumor vasculature (Bergers et al., 2003), reducing vascular
density and functionality rather than producing the vasculariza-
tion characteristic of less potent AI such as bevacizumab.
Although both compounds have a similar target profile, axitinib
exhibits fewer off target effects and toxicity (Gunnarsson et al.,
2015) (http://www.accessdata.fda.gov). In the course of further
characterizing cellular and histologic responses to the two
drugs, in particular their effects on the aforementioned mTOR
signaling pathway, we observed an intriguing switch in the
pattern of mTOR activity, reflected by phosphorylation of its
downstream effector S6. Specifically, the diffuse pattern seen
in untreated tumors was replaced by one of focal clusters. This
focal reorganization of mTOR signaling motivated the investiga-
tion reported below, where we implicate metabolic symbiosis as
another mode of adaptive resistance to anti-angiogenic therapy.
RESULTS
Sunitinib/Axitinib Treatment Affects mTOR Signaling in
Mouse PanNET
Given thatmTOR signaling is prominently involved in the PanNET
phenotype (see above), we had askedwhether it was affected by
disruption of the tumor vasculature with sunitinib. Indeed, mTOR
signaling was found to be elevated in a set of sunitinib-treated
tumors, as reflected in the heightened levels of phospho-S6 ki-
nase (p-S6). In contrast, sunitinib treatment of cultured mouse
PanNET cells did not elicit this upregulation (data not shown).
To substantiate this observation, molecular efficacy trials were
performed with sunitinib, in which mice with late stage tumors
were treated for 7 days followed by analysis of tumor lysates
by western blotting. Sunitinib elicited an increase in p-S6 (Fig-
ure 1A, left), which was blocked by concomitant administration
of the mTOR inhibitor rapamycin (Figure 1A, right), demon-
strating that its upregulation is mTOR dependent. Axitinib-
treated tumors produced a similar trend (data not shown).
The elevated mTOR signaling was surprising in that sunitinib-
and axitinib-treated tumors become hypoxic in response to
collapse of the tumor vasculature (Pa`ez-Ribes et al., 2009; Sen-
nino et al., 2012), and observations presented below), andmTOR
is typically downregulated in hypoxic conditions (Brugarolasmice were treated daily (see Supplemental Information) with vehicle control (Co
combination of the two (R+S) (top right). The lysates were normalized to actin by
reprobed for actin normalization.
(B) The bTC4 cell line was cultured in normoxic (20%O2/5%CO2) or hypoxic (1%
above.
(C) Tissue sections from tumors treated for 4 weeks in an intervention trial (see Fig
representative images are shown. The scale bars represent 100 mm.
(D) Representative images from tissue sections of tumors treated with sunitinib
hypoxia (right), p-S6 reactivity (red, arrowheads) indicates that mTOR/p-S6 sign
images are shown in the left image. The scale bars represent 50 mm.
(E) A highly regressed sunitinib-treated tumor after 8 weeks of Mono-S (13–21 we
tissue, which are organized around the few remaining blood vessels (CD31, blue,
all others.
1146 Cell Reports 15, 1144–1160, May 10, 2016et al., 2004). Indeed, a derivative PanNET cancer cell line
(bTC4) downregulated p-S6 in hypoxic versus normoxic condi-
tions (Figure 1B). Intrigued by this apparent dichotomy, we
further investigated mTOR signaling in tumors treated for
4 weeks using immunohistochemistry. As shown in Figure 1C,
p-S6 was elevated in sunitinib-treated tumors, but its expression
was relocalized from the diffuse pattern seen in control tumors
into focal clusters. The specificity of the p-S6 staining in control
and sunitinib-treated tumors was confirmed by treatment with
rapamycin, which ablated p-S6 expression, even when dosed
in combination with sunitinib.
Next, we assessed the relationship between p-S6 expression
and hypoxia in treated tumors. Co-staining of sunitinib- and ax-
itinib-treated tumors with antibodies to p-S6 and pimonida-
zole—to reveal regions of hypoxia—revealed an anti-correlation:
p-S6 was predominantly expressed in the normoxic, and not
hypoxic, regions of the treated tumors (Figure 1D).
Eventually, as the vascular regression and inhibition of new
growth continues, the normoxic regions seen in Figure 1D can
coalesce into the focal clusters seen in Figure 1C. This is further
illustrated in Figure 1E, which shows a highly necrotic/hypoxic
tumor (left); within the regions of fibrosis/necrosis, focal clusters
of viable cancer cells can be seen (H&E, middle left). These clus-
ters are highly proliferative (Ki-67, middle right) and are cuffing
blood vessels (CD31, right).
AI Treatment ofMouse PanNETs Produces Upregulation
of Glucose and Lactate Transporters in Patterns
Suggestive of Metabolic Symbiosis
The clustering of viable cancer cells around the few remaining
blood vessels inside long-term treated tumors is consistent
with their need for oxygen, but also for blood-borne nutrients,
in particular glucose. We performed short-term trials using suni-
tinib alone or in combination with rapamycin and then performed
RNA-sequencing (seq) analysis on the treated and control tu-
mors. We conducted enrichment analysis on the top 2,500 un-
regulated genes in the control versus treated tumors, and the
top ten enriched hallmark pathways for sunitinib monotherapy
are depicted in Figure 2A, including hypoxia and glycolysis.
The enrichment plot for the hallmark glycolysis signature
(Figure 2A) includes Slc16a3 (MCT 4) and Ldha (lactate
dehydrogenase A; Figure 2B), along with (to a lesser degree)
Slc2a1 (GLUT1, data not shown). Both sunitinib and axitinib pro-
duced marked reductions in tumor vasculature (Figure S1A) with
widespread hypoxia, consistent with the hypoxia signature.n), rapamycin monotherapy (Mono-R), sunitinib monotherapy (Mono-S), or a
WB, blotted, and probed with anti-p-S6 as a readout for mTOR signaling and
O2/5%CO2) conditions, and the lysates were prepared and analyzed byWB as
ure 4A for a description of trial formats) were used for IHC using anti-p-S6. The
(top) or axitinib (bottom). Pimonidazole (pimo, green) staining indicates tumor
aling is mostly excluded from the hypoxic regions (middle), and the merged
eks). The islands of highly proliferative cells (Ki-67+) are embedded in fibrotic
arrows). The scale bar represents 700 mm in the leftmost image and 200 mm in
Figure 2. Gene Specific Expression Analysis
Reveals a Strongly Glycolytic Signature in
Mono-S-Treated Tumors
(A) Gene set overlapping analysis on the top
2,500 upregulated genes in sunitinib treatment
compared to vehicle treated controls, revealing
that glycolysis and hypoxia were among the most
enriched pathway signatures (left). The glycolysis
enrichment plot for sunitinib-treated tumors,
including the profile of running ES Score are shown
(right).
(B) Top five ranked genes from the hallmark
glycolysis gene set, adopted from the Molecular
Signatures Database of the Broad Institute, for the
sunitinib-treated cohort.
(C) MCT4 expression was assessed using IHC on
15 week control tumors (Con, left) and tumors
treated with rapamycin monotherapy (Mono-R,
middle left), axitinib (Mono-A, middle right), or su-
nitinib (Mono-S, right). The MCT4 expression is
high in 4/4 larger and 5/6 smaller Mono-A- and 4/4
larger Mono-S-treated tumors and absent in Con
and Mono-R-treated tumors. The scale bars
represent 2 mm in top image and 200 mm in the
bottom image.
(D) Pimonidazole (pimo, green) staining was per-
formed to assess tumor hypoxia (center left); the
glucose transporter, GLUT1, is shown in red
(center right), and the leftmost image depicts the
merged images. A merged image of R+A-treated
tumors for MCT4 and pimonidazole is depicted
in the rightmost image. The GLUT1 and MCT4
staining is highest in the most pimonidazole+/
hypoxic regions, but can also be found in the
peri-hypoxic areas. The scale bars represent
100 mm in the three left images and 50 mm in the
right image.
(E) IHC using anti-GLUT1 (middle) and anti-MCT4
(right) indicates that their expression is highly
reduced/absent in tumors containing a cell-type-
specific (b-cell) gene knock out of HIF1a that were
treated with sunitinib. The top row shows a repre-
sentativeRip1Tag2_Rip1Cre_Hif1aWT tumor,while
the bottom row shows a Rip1Tag2_Rip1Cre_
Hif1afl/fl littermate whose tumors do not express
Hif1a; this result is representative of all tumors from
4/4 wild-type (WT) versus 6/6 HIF1a KO mice, all
similarly treated with sunitinib. The scale bar repre-
sents 100 mm.
(F) Monotherapy with sunitinib (middle row) or
axitinib (bottom row) elicits upregulation of MCT4
(green, first, second, and fourth) versus control
untreated tumors (top row); in addition, MCT1 (in
red) is upregulated in both AI-treated arms (middle
and bottom rows, first, third, and fourth) versus
controls (top row, first, third, and fourth). The scale
bar represents 25 mm.Motivated by the glycolysis signature and the known induction of
glycolysis by hypoxia, we assessed expression by immunostain-
ing for the lactate transporter MCT4 and the glucose transporter
GLUT1, whose elevated co-expression is diagnostic of glycol-ysis (Ullah et al., 2006). Concordantly, the striking upregulation
of Slc16a3/MCT4 revealed by the RNA profiling of sunitinib-
treated tumors was detected by immunohistochemistry in tissue
sections from the majority of sunitinib- and axitinib-treatedCell Reports 15, 1144–1160, May 10, 2016 1147
tumors and was very low/absent in control or rapamycin-treated
tumors (Figure 2C). In treated tumors, GLUT1 and MCT4 were
upregulated in the hypoxic regions, as revealed by co-staining
with pimonidazole (Figure 2D). Such upregulation in hypoxic
conditions is consistent with previous reports that GLUT1 and
MCT4 are regulated by the HIF hypoxia response system (Ebert
et al., 1995; Ullah et al., 2006; Seagroves et al., 2001). To confirm
this interpretation, we evaluated compound mice carrying a tis-
sue-specific gene knock out of HIF1a in the oncogene-express-
ing cancer cells. Indeed, sunitinib treatment failed to upregulate
GLUT1 andMCT4 in the Hif1a-knockout (KO) tumors (Figure 2E),
supporting the expectation that HIF1a drives their upregulation.
The compartmental expression of GLUT1/MCT4 was reminis-
cent of a phenomenon—observed in certain tumors—known as
metabolic symbiosis, wherein hypoxic regions import and
metabolize glucose (Ebert et al., 1995) and secrete lactate, while
normoxic regions import and metabolize the lactate (Sonveaux
et al., 2008; Kennedy et al., 2013). We therefore assessed
expression of the lactate transporter MCT1 and found that it
was upregulated in a distinct compartment from the hypoxic,
MCT4 positive region (Figure 2F), although a small minority of
cells are MCT1+/MCT4+ double positive (Figure S1B).
Mouse PanNET Tumors and Cell Lines Consume and
Catabolize Lactate to Establish Metabolic Symbiosis
The hypothesis of metabolic symbiosis demands that the
secreted lactate is not merely ‘‘toxic acidic waste’’, but rather
a source of fuel that is imported and metabolized by the nor-
moxic cancer cells. We assessed whether cultured bTC3 cells
could recapitulate key aspects of the hypoxic response in culture
and found that GLUT1 and MCT4 were upregulated under
hypoxic conditions (Figure 3A). We further assessed lactate uti-
lization in cultured cancer cells and in tumor-bearing mice, by
supplying isotopically labeled lactate or glucose, and assessing
their catabolism into metabolites by NMR spectroscopy (Figures
3B and 3C). Thus, bTC3 cancer cells were cultured in hypoxic
and normoxic conditions, in which they were supplied with
1–13C-glucose or with 3–13C-lactate in glucose-free media, in
both cases similarly supplemented with glutamine and fetal
calf serum (FCS); after 20 hr, the cells were harvested for NMR
analysis. At this time point, cells cultured in 1–13C-glucose
increased the levels of lactate in conditioned media both in hyp-
oxia and normoxia, whereas cells cultured in 3–13C-lactate
reduced the levels of lactate in conditioned media under
normoxia and slightly increased lactate in hypoxic conditions
(Figure 3B, legend). The 13C NMR analysis revealed that in
aerobic conditions 3–13C-lactate was catabolized to C4-gluta-
mate, C2- and C3-aspartate (Asp), and C3-alanine (Figure 3B),
consistent with previous studies on lactate metabolism by can-
cer cells and neurons (Kennedy et al., 2013; Waagepetersen
et al., 1998; Yang et al., 2014). In contrast, lactate was
imported, but not catabolized in hypoxic conditions (Figure 3B).
Notably, the lactate catabolites coincide with those produced by
1–13C-glucose, indicating that both sets are likely produced
through the same intermediate, pyruvate.
Next, tumor-bearing mice treated for 10 days with sunitinib,
rapamycin+sunitinib, or vehicle control were infused with
3–13C-lactate and the tumors excised and evaluated by NMR.1148 Cell Reports 15, 1144–1160, May 10, 2016Both treated and control tumors metabolized lactate (Figure 3C).
Additionally, the branched metabolic pathways involved in
lactate catabolism may be altered in activity. The prominent
3–13C-alanine band produced from 3–13C-lactate/ 3–13C-pyru-
vate + glutamate / 3–13C-Ala + a-ketoglutarate is relatively
undiminished versus the glutamate and Asp species in the suni-
tinib-treated tumors; notably, the pathway producing 3–13C-Ala +
a-ketoglutarate is involved in sustaining tricarboxylic acid (TCA)
cycle intermediates important both for energy production and
biosynthesis of cellular building blocks, a process referred to
as anaplerosis. Intriguingly, RNaseq and RT-quantitative (q)
PCR analysis (Table S1) of sunitinib versus control tumors re-
vealed upregulation of Gpt2, an aminotransferase catalyzing
the transamination that produces alanine + a-ketoglutarate
from pyruvate and glutamate. In addition, Gls2, which converts
glutamine to glutamate in the first step of its metabolism, is
also upregulated (Table S1). In contrast, the rapamycin+suniti-
nib-treated tumors did not produce 3–13C-Ala. Rather, lactate-
derived pyruvate evidently was converted to acetyl-CoA to enter
the TCA cycle, producing C2- and C4-glutamate and C2- and
C3-Asp (Figure 3C). Thus, the data suggest that glutamine-asso-
ciated catabolism of lactate to alanine becomes favored in the
context of sunitinib therapy, which in the combination-treated
tumors is repressed—directly or indirectly—by mTOR inhibition.
Collectively, these observations, along with previous studies
indicating the link between glutamine metabolism and mTOR
signaling (Csibi et al., 2014; Dura´n et al., 2012), led us to consider
the possible involvement of glutamine and the observed meta-
bolism of lactate in the induction of mTOR signaling.
mTOR Signaling in Cultured Cancer Cells can Be
Upregulated by Lactate and Glutamine Metabolism
Motivated by the observation that expression of Gls2 was
increased in sunitinib-treated tumors (Table S1), we asked
whether it was expressed in the hypoxic or normoxic compart-
ment. Analysis of sunitinib-treated and control untreated tumors
by fluorescent staining with anti-glutaminase 2 (GLS2) and pimo-
nidazole demonstrated elevated expression of glutaminase 2 in
both cases, and it could be found in both normoxic and hypoxic
compartments in sunitinib-treated tumors (Figure 4A), a result
that was substantiated via RT-qPCR analysis of bTC3s cultured
under normoxic and hypoxic growth conditions (Table S2); we
also analyzed additional metabolic genes for differential expres-
sion and found significant upregulation of Slc2a1, Slc16a3, and
Ldha in hypoxic conditions, whereas Slc2a2, Ldhb, and Gpt2
were elevated in normoxic growth conditions (Table S2).
Next, we investigated possible links between glutamine,
lactate metabolism, and mTOR signaling. First, we assessed
the importance of glutamine for cell proliferation of bTC3 cells
by EdU incorporation, which revealed minimal difference
between the various culture conditions containing glutamine,
with or without glucose and/or lactate; there was, however, a
block in cell-cycle progression under glucose without glutamine
conditions (w/wo lactate) (Figure S2A), highlighting the depen-
dence of these cells on glutamine. Then, we evaluated mTOR
signaling in bTC3 cells (Figure 4B) cultured in different combina-
tions of lactate and glutamine. Cells were cultured in FCS and
glutamine-supplemented, glucose-free media, with or without
(legend on next page)
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lactate. Net changes in lactate levels in conditioned media (CM)
were assessed. Lactate levels in glutamine-supplemented,
glucose-free cell media decreased reproducibly under aerobic
conditions, consistent with its uptake by bTC3 cells (Figures
4B and S2B). Moreover, there was significant upregulation of
p-S6 levels in cells cultured in lactate + glutamine versus gluta-
mine alone (Figure 4B, top and bottom), correlating with a net
reduction of lactate in CM. As expected, upregulation of p-S6
could be reversed by rapamycin. Notably, p-S6 upregulation
could also be reversed by inhibiting lactate uptake with CHC or
7ACC2, two distinctive inhibitors of theMCT1 lactate transporter
(Sonveaux et al., 2008; Draoui et al., 2014) (Figure 4B, top and
bottom). In addition, a glutaminase inhibitor, DON (Dura´n et al.,
2012) (Figure 4B, top and bottom), and an alanine aminotrans-
ferase inhibitor, AOA (Lamonte et al., 2013) (Figure 4B, top),
also reversed p-S6 upregulation, whereas a glutaminase 1-spe-
cific inhibitor, BPTES, did not (Figure 4B, bottom). We observed
similar effects of lactate and glutamine on mTOR signaling in
lactate-avid SiHa ovarian cancer cells (Figure S2C), which have
been extensively used to study metabolic symbiosis (Sonveaux
et al., 2008). Collectively, the data support a mechanism
whereby cancer cells take up and metabolize lactate in the
context of bioavailable glutamine in normoxic, but not hypoxic
conditions (Figures 3B and 3C), thereby upregulating mTOR
signaling (Figure 4B). A schematic depicting the branched meta-
bolic pathways involved in lactate catabolism in control and
treated Rip1Tag2 PanNET tumors is depicted in Figure S2D. In
addition, we found that bTC3 cells cultured in lactate + glutamine
upregulated a-ketoglutarate compared to cells cultured in gluta-
mine only (Figure 4C). Concordantly, Sonveaux and colleagues
recently reported a link between lactate and glutamine meta-
bolism in cultured SiHa and HeLa cancer cells under oxidative
conditions (Pe´rez-Escuredo et al., 2016).
Effects of Co-targeting Angiogenesis and mTOR
Signaling
In light of the proposition that potent AIs were inducing tumors to
adapt a strategy ofmetabolic symbiosis, and the observed reloc-
alization of mTOR signaling into the normoxic compartment of
putative symbiotic clusters, we investigated the impact of
blocking mTOR signaling on the AI-induced symbiosis and
consequent tumor phenotypes. Regression trials (depicted in
Figure 5A) were initiated at 13 weeks, when the mice already
had appreciable tumor burden, and continued to a defined
endpoint 2 weeks later (15 weeks), whenmost untreated animals
have succumbed to hypoglycemia attributable to increased in-Figure 3. Mouse PNET Cell Lines and Tumors Consume and Cataboliz
(A) bTC3 cancer cells cultured in normoxic conditions show low levels of GLUT1 (g
hypoxic conditions. The scale bars represent 25 mm.
(B) NMR analysis of bTC3 cells, cultured in low glucose (6.25 mM glucose + 2 mM
glucose/0% Gln + FCS ON, then plated in 20 mM 1–13C-glucose + 2 mM Gln +F
(1%O2/5% CO2) or normoxic conditions (20%O2/5%CO2), and harvested for NM
in hypoxia was +15.6 mM and normoxia +4.6 mM, while 3–13C-lactate levels were
The gray arrow highlights 4–13C-glutamine, which was found as a product of 3–13C
shown).
(C) Tumor-bearing mice were treated for 10 days with Mono-S or R+S, or vehicle
tumors were excised, quick frozen in liquid nitrogen, and prepared for NMR (see
1150 Cell Reports 15, 1144–1160, May 10, 2016sulin secretion from the multiple pancreatic tumors that develop.
Reasoning that vascular collapse might affect the bioavailability
of rapamycin in the tumor microenvironment, we tested a trial
regimen in which R+S and R+A arms were dosed for an initial
2D with rapamycin alone, followed by continuous dosing in
combination with the AI (called ‘‘stagger’’ or ‘‘St’’). Another
cohort of R+S was dosed simultaneously with both drugs from
the beginning (‘‘simultaneous’’ or ‘‘Sim’’). All three monothera-
pies (Mono-S, red triangles; Mono-R, yellow triangles; and
Mono-A, green circles) showed anti-tumor activity, blocking
further growth to produce tumor stasis compared to 13 week
controls (Figure 5B, blue circles). In marked contrast, each of
the combinations of rapamycin plus an AI (R+S-St, purple dia-
monds; R+S-Sim, purple triangles; and R+A-St, rose squares)
produced significant tumor regression versus the 13 week start-
ing time point (Figure 5B, blue circles). An additional 4-week-long
intervention trial was performed with sunitinib, starting at
11 weeks, when the tumors were smaller, until the same defined
15 week endpoint (Figure 5C). Again, while Mono-S (red trian-
gles) and Mono-R (yellow triangles) produced significantly
smaller tumors than vehicle-treated controls (blue circles), their
combination (R+S-St, purple diamonds and R+S-Sim, purple tri-
angles) produced significantly lower tumor burden than either
efficacious monotherapy. Other dosing strategies were also as-
sessed, including a shift from Mono-R to Mono-S (Figure 5C,
R->S, green circles), which appeared indistinguishable from
each monotherapy in regard to tumor burden (TB). There was
also an efficacious response to the combination R+S when
sunitinib was reduced by half (Figure 5C, R+1/2S, blue-gray cir-
cles). Thus, both experimental therapeutic trials demonstrated
anti-tumoral efficacy for the combination of the mTOR inhibitor
rapamycin and a potent AI.
In order to further characterize the therapeutic response, open
endpoint survival trials were performed with the combinations, in
comparison to monotherapy- and vehicle-treated controls. Co-
horts of micewere treated starting at 13weeks until they became
moribund and were sacrificed (Figure 5D). All treatments,
including the monotherapy arms, led to a significant survival
advantage versus vehicle-treated mice. End stage tumors had
progressed to a considerable size on rapamycin monotherapy,
larger on average than untreated controls, indicating an adaptive
resistance involving enhanced growth rates (Figure S3A), as re-
ported previously (Chiu et al., 2010). Overall, TB at end stage
was higher in regimens involving axitinib versus sunitinib (Fig-
ure S3A). Interestingly, both AIs produced tumors that never re-
vascularized (data not shown). Additionally, the combinatione Lactate to Establish Metabolic Symbiosis
reen) and MCT4 (green) expression, whereas both proteins are upregulated in
Gln + FCS), plated in the same media at 7 3 106 for 2 days, switched to 0%
CS (top) or 20 mM 3–13C-lactate + 2 mM Gln+ FCS, cultured 16 hr in hypoxic
R. The net production of lactate in CM from time 0 in 1–13C-glucose conditions
either increased in hypoxia by +0.4 mM or reduced in normoxia by 2.7 mM.
-lactate catabolism in bTC3 cells when these results were replicated (data not
control, and then infused with 3–13-C-lactate for 90 min prior to sacrifice. The
Experimental Procedures).
Figure 4. Metabolic Regulation of mTOR Signaling
(A) Pimonidazole (green) is merged with anti-GLS2 (red) in left
images, and right images depict tumors anti-GLS2 only (red) in
control untreated tumors (top) and sunitinib-treated tumors
(bottom). The arrow indicates GLS2-negative staining, while the
arrowhead indicates GLS2-positive staining in hypoxic cells.
The scale bars represent 25 mm.
(B) bTC3 cells, acclimated to low glucose as in Figure 3, were
cultured in 2mMglutamine (Gln), or 2mMGln + 20mM lactate ±
selective metabolic inhibitors, and assessed for p-S6 levels.
Both bTC3s and lactate avid SiHa cells (Figure S2C) markedly
upregulated p-S6 when cultured in lactate + Gln versus Gln
alone; this upregulation could be reversed by 100 nM rapa-
mycin treatment, or partially reversed using 40 mM DON, a
competitive inhibitor of glutaminase. In addition, blocking
lactate uptake with the MCT1 inhibitors 1 mM CHC or 10 mM
7ACC2 also reversed this upregulation, as did 200 mM AOA,
which blocks the transamination of pyruvate + glutamate to
alanine + a-ketoglutarate. The bottom images depict experi-
ments performed with the selective GLS1 inhibitor, 50 mM
BPTES, which failed to reverse the lactate induced pS6 upre-
gulation, in contrast to DON, CHC, or 7ACC2. Below the blot is
a graphic depicting the net consumption or production of
lactate from time = 0.
(C) Graphic depicting the relative production of a-ketoglutarate
in Gln + lactate versus Gln-only conditions. The samples were
normalized by protein concentration.
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therapies reduced the frequency of metastasis compared to
both AI monotherapies, despite the significantly longer survival
of mice in the dual therapy arms (Figure S3B). It is unclear why
themicewith only residual TBwere dying, which is a topic worthy
of future investigation.
mTOR Inhibition Disrupts Metabolic Symbiosis
The combination of rapamycin plus sunitinib treatment for
1–2 weeks reproducibly elicited tumor regression, characterized
by widespread necrosis and fibrosis, and markedly reduced
proliferation, particularly in large tumors (Figures S4A, S4B,
and S6). In contrast, while 8 weeks of Mono-S also produced
tumors with pronounced necrosis and fibrosis, the remaining
tumor cells were highly proliferative (Figure 1E). When 13- to
15-week-treated tumors were analyzed comparatively for prolif-
eration rates via Ki-67 staining, there was a significant reduction
in proliferation in R+S-treated tumors versus controls and both
monotherapies (Figure S4B). Tumors treated with Mono-R had
limited necrosis (data not shown), consistent with this and our
previous study indicating it elicited heighted rates of apoptosis
without appreciable necrosis (Chiu et al., 2010) (Figure S4C).
Seeking to understand the basis for this heightened necrosis,
and having identified putative symbiotic clusters of cancer cells
associated with remaining blood vessels in the Mono-S-treated
tumors, we asked whether rapamycin was affecting symbiosis in
the R+S-treated tumors. The clusters could still be detected, as
revealed by co-staining with MCT1 and MCT4, but their
morphology was altered. Surprisingly, we observed that cancer
cells in the hypoxic GLUT1high, MCT4high, and mTORlow
compartment were selectively depleted compared to those cells
in the normoxic GLUT1low, MCT1high, and mTORhigh regions
where rapamycin was acting to suppress mTOR signaling.
Only a rim of MCT4 cells could be detected, flanking regions of
necrosis, in contrast to the multiple layers of such cells seen in
the Mono-S-treated tumors (Figure 6A). In contrast, rapamycin
did not obviously disrupt the (previously p-S6high) MCT1high
compartment (Figure 6A). Thus, inhibition of mTOR signaling in
the normoxic compartment was disrupting the symbiosis, but
via an unexpected paracrine mechanism.
A tenant of the symbiosis hypothesis is that the normoxic can-
cer cells have not upregulated glucose transporters, in contrast
to the hypoxic cells (Figure 2D), thereby sparing limited bioavail-
able glucose to diffuse from the nearest blood vessel to distal,
but still viable hypoxic cancer cells. We wondered, therefore, if
mTOR inhibition affected expression of glucose transporters?
We first surveyed untreated tumors and observed heteroge-
neous expression of GLUT1 and a related transporter GLUT2,
which is involved in glucose homeostasis in pancreatic islets
(Guillam et al., 1997) (Figure S5A). A third transporter, GLUT3,
was not consistently expressed (data not shown). Mono-S-
and R+S-treated tumors were stained with antibodies that
recognized pimonidazole adducts, indicative of hypoxia, and
anti-GLUT1 and anti-GLUT2 antibodies (Figure 6B). The analysis
revealed appreciable upregulation of GLUT2 expression (red
staining) in the normoxic regions of R+S, but notMono-S-treated
tumors (Figure 6B, bottom); the Mono-S tumors express very lit-
tle GLUT2 (or GLUT1) in normoxic regions proximal to the ves-
sels. In contrast to GLUT2, GLUT1 is not widely upregulated in1152 Cell Reports 15, 1144–1160, May 10, 2016the normoxic compartment of R+S-treated tumors. We also per-
formed comparative IHC using automated staining with GLUT1
and GLUT2 and saw a similar upregulation of GLUT2 in the nor-
moxic regions of R+S- versus Mono-S-treated tumors (Fig-
ure S5B). Western blot analysis on tumors also confirmed
GLUT2 upregulation in R+S-treated tumors versus Mono-S
(Figure S5C), as did qRT-PCR (Table S1). There was also a
modest upregulation of GLUT2 in bTC3 cells cultured in glutami-
ne+lactate+rapamycin versus glutamine ± lactate (Figure S5D),
conditions we believe may be a surrogate for those found in
the oxidative cancer cells inside AI-treated tumors. Although
consistent with the in vivo results, further work is required to sub-
stantiate these findings and determine the molecular pathway
that governs this regulation. Thus, we envision that the normoxic
compartment of the putative symbiotic clusters switches, in the
context of mTOR inhibition, to importing and metabolizing
blood-borne glucose instead of sparing it to favor lactate.
Consequently, the vascular non-proximal hypoxic cells would
starve from glucose deprivation and die; likely exacerbated by
lactic acidosis, since the normoxic cells are now net secretors
of lactate as a consequence of aerobic glycolysis. Transmission
electron microscopy (Figure S6) of cancer cells in the peri-
necrotic region of a R+S-treated tumor reveals cells with
granulated cytoplasm and grossly distended mitochondria,
and abundant insulin granules, potentially indicative of the
extreme conditions of insufficient oxygen and glucose, and an
acidic microenvironment. To further substantiate these associa-
tions, Figure S7 shows images of additional Control, Mono-S-,
and R+S-treated tumors on serial sections stained with anti-
MCT1, anti-MCT4, and pimonidazole, matched with anti-phos-
pho-S6 ribosomal protein (pS6), -GLUT1, and -GLUT2. These
images further document the upregulation of MCT1/4 in
Mono-S- and R+S-treated tumors versus untreated controls
and abundant MCT1 staining in the R+S tumors. The pimo-
nidazole/pS6 panels show strong and relatively homogenous
staining of pS6 in non-hypoxic control tumors, and compartmen-
talized pS6 staining in the normoxic regions of Mono-S tumors,
but no reactivity in the R+S-treated tumors. The TEM and immu-
nostaining analysis both support the interpretation that the hyp-
oxic compartment is being eliminated faster than the normoxic
one in the R+S-treated tumors.
DISCUSSION
In this and the two companion reports in this issue of Cell Re-
ports from Pisarsky et al., 2016 and Jime´nez-Valerio et al.,
2016, we describe an unanticipated newmode of adaptive resis-
tance—metabolic symbiosis—that is induced in response to
potent anti-angiogenic therapies that cause vascular collapse
and consequent hypoxia. We show that cancer cells compart-
mentalize themselves in the acute condition of vascular insuffi-
ciency into comparatively hypoxic and normoxic compartments,
based on their relative proximity to the few remaining functional
blood vessels. The hypoxic cancer cells induce expression of the
glucose importer GLUT1 and the lactate exporter MCT4, which
is dependent on HIF1a. The normoxic cells express the lactate
transporter MCT1, and we show that both normoxic cancer cells
in culture and tumors in vivo import and catabolize lactate; thus
Figure 5. Therapeutic Targeting of AI-Induced, p-S6+ Clusters with Rapamycin
(A) Trial designs are indicated in this schematic: trials were initiated and terminated at discrete time points, as established by previous studies in the Rip1Tag2
model (Bergers et al., 1999). The intervention trials were initiated at 11weekswhen tumorswere small (Figure 5C), while fixed endpoint regression trials (Figure 5B)
and open endpoint survival trials (Figure 5D) were initiated at 13 weeks when tumors were already large; molecular efficacy trials commenced at 13.5–14 weeks
and proceeded for 7–10 days.
(legend continued on next page)
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lactate is not just toxic waste from glycolysis, but rather is being
used for energy metabolism. Moreover, our data reveal that the
metabolic branch of lactate catabolism involving glutamine
metabolism is favored, and this branch is blocked in tumors
treated with rapamycin and anti-angiogenic therapy. Moreover,
PanNET cancer cells cultured in the presence of lactate and
glutamine upregulate phospho-S6 ribosomal protein (p-S6);
the proposition that glutamine metabolism upregulates mTOR
activity is consistent with previous studies in other cell culture
systems (Dura´n et al., 2012). The association of lactate and
glutamine catabolism in the regulation of mTOR in these condi-
tions of stressful vascular insufficiency is further substantiated
by our results showing that mTOR upregulation can be sup-
pressed by impairing lactate uptake with known inhibitors of
MCT1, or by inhibiting enzymes involved in glutaminolysis,
namely glutaminase 2 that converts glutamine to glutamate in
the first step of its metabolism and an alanine aminotransferase
that in turn catalyzes the production of alanine + a-ketoglutarate
from (lactate-derived) pyruvate and glutamate. Other studies
have reported that mTOR regulates glutamine flux and gluta-
minase levels (Csibi et al., 2014).
The observed upregulation/segregation of mTOR activity into
the normoxic cell compartment induced by two potent AIs, and
the resultant putative metabolic symbiosis, can be disrupted
by concomitant inhibition of mTOR signaling with rapamycin.
Remarkably, the initial impact of inhibiting mTOR in normoxic
cancer cells is the necrotic death of the hypoxic cells, which
lack elevated levels of mTOR signaling. An explanation for this
intercellular crosstalk is offered by the observation that another
glucose importer, GLUT2, is upregulated in normoxic peri-
vascular cancer cells in response to rapamycin. The data sug-
gest that the normoxic cancer cells proximal to the few remaining
vessels consume the available blood-borne glucose when
mTOR is inhibited, thereby starving distal hypoxic cancer cells,
leading to their demise. Additionally, our NMR analysis of tumors
suggests that mTOR inhibition blocks lactate catabolism via the
anaplerotic pathway, and this abrogation of lactate consumption
may lead to the intra-cellular and peri-cellular accumulation of
toxic levels of lactate. The regulatory pathways involved in
GLUT2 induction and metabolic reprogramming when the nor-(B) Fixed endpoint regression trials were performed from 13–15 weeks, as descr
a two-tailed Mann-Whitney test was used to assess statistical significance; 13 w
R+S Sim, p = 0.0003***; 15 week TP control versus Mono-R, p = 0.02*, R+S S
p = 0.0005***; Mono-R versus R+S Sim, p = 0.0008***; Mono-S versus R+S St,
(*p = 0.05–0.01, **p = 0.009–0.001, and ***p < 0.001).
(C) Fixed endpoint intervention trials were performed for 4 weeks, commencing a
are indicated. Two-tailedMann-Whitney test for statistical significance; 11–15wee
p = 0.0001***, R+S Sim, p = 0***, and 1/2R+1/2S andR+1/2S, p = 83 105;Mono-R
p = 0.0009*** and R+S Sim, p = 0.0001***; R->S versus R+S St, p = 0.0032** and
p = 0.002**; and 1/2R+1/2S versus R+S Sim, p = 0.0009*** (*p = 0.05–0.01, **p =
(D) Open endpoint survival trials were performed in Rip1Tag2 mice from 13 wee
composed of 7–12 mice/arm, and p values were derived using the log rank test
control vehicle-treated mice (n = 10; 16.9 ± 0.8 weeks); Mono-S (n = 10; 21.8 ± 1.6
and R+S St (n = 9; 24.51 ± 3.3 weeks), R+S Sim (n = 7; 25.4 ± 3.8 weeks), and R+A
than the other arms, signified by a stippled line, and was not statistically differen
arms were sacrificed for evaluation of TB and metastasis at the following time p
28.4 weeks. All of the treated arms show significantly higher survival than the vehic
R+S St versus Mono-S, p = 0.015*; R+A St versus Mono-A, p = 0.002**; and Mo
See also Figures S3A and S3B.
1154 Cell Reports 15, 1144–1160, May 10, 2016moxic compartment is subjected to mTOR inhibition warrant
future investigation.
Remarkably, as summarized in the introduction, multiple
modes of adaptive or evasive resistance to therapies targeting
tumor angiogenesis have been reported (Casanovas et al.,
2005; Shojaei and Ferrara, 2008; Bergers and Hanahan, 2008;
Ebos et al., 2009; Pa`ez-Ribes et al., 2009; Sennino et al., 2012)
in experimental therapeutic trials performed using conventional
transplant and genetically engineered de novo mouse models
of cancer. Of these, only heighted invasiveness has been clearly
implicated as an adaptive resistance mechanism in a human
cancer, namely glioblastoma (Lu and Bergers, 2013; and refer-
ences therein), although similar mechanisms can be envisioned
to underlay the transitory clinical responses to AI therapy in
virtually all tested forms of human cancer. Notably, the accom-
panying report by Jime´nez-Valerio et al. (2016, this issue of
Cell Reports) documents the induction of MCT1/MCT4 lactate
transporters in a pattern consistent with metabolic symbiosis
in renal cell carcinoma (RCC) patient-derived xenograph tumor
(PDX) models treated with AI therapy. Moreover, analysis of bi-
opsies of tumors from RCC patients treated with sunitinib pro-
duced histologic signatures of metabolic symbiosis that were
exacerbated in relapsing/progressing (resistant) tumors from pa-
tients on anti-angiogenic therapy. Their data further show that
this metabolic patterning is associated with TOR signaling, since
its inhibition can evidently block this characteristic patterning.
This study in human RCC, along with the accompanying article
by Pisarsky et al. (2016, this issue of Cell Reports) in a mouse
model of breast cancer and the results presented herein collec-
tively and compellingly add metabolic symbiosis to the roster of
adaptive/evasive resistance mechanisms to anti-angiogenic
therapy.
In a broader context, the existence of metabolic symbiosis in
tumors has been previously reported by Dewhirst, Sonveaux,
Feron, and colleagues to arise spontaneously in certain trans-
plant tumor models (Kennedy et al., 2013; Sonveaux et al.,
2008; Semenza, 2008). They have described in a series of publi-
cations ametabolic symbiosis that conveyed decreased reliance
on bioavailable glucose that limited the collateral damage from
secreted lactate and consequent lactic acidosis, achieved byibed in the Supplemental Information. Mean values ± SEM are indicated, and
eek timepoint (TP) control versus R+S St and R+A St, p = 0.003** and versus
t, p = 0.0003***, R+S Sim, p = 0.0004***, Mono-A, p = 0.006**, and R+A St,
p = 0.044* and R+S Sim, p = 0.0008***; and Mono-A versus R+A, p = 0.004**
t 11 weeks, and described in Supplemental Information. Mean values ± SEM
k vehicle control versusMono-R andMono-S, p = 0.0004***, RRS and R+S St,
versus R+S St, p = 0.036* andR+S Sim, p = 0.0006***; Mono-S versus R+S St,
R+S Sim, p = 8 3 105*** and R+1/2S (p = 0.0023**); R+S St versus R+S Sim,
0.009–0.001, and ***p < 0.001).
ks of age until animals became moribund and were sacrificed. Cohorts were
(LR). Survival was assessed for each cohort as mean survival in weeks ± SD:
weeks); Mono-R (n = 10; 22.9 ± 1.7 weeks); Mono-A (n = 12; 21.7 ± 2.2 weeks);
St (n = 9; 25.8 ± 4.4 weeks). The R+S Sim arm was comprised of fewer animals
t than each cognate monotherapy. Long surviving, healthy mice from different
oints: R+S St, 30.4 weeks; R+S Sim, 30.1 weeks; and two mice from R+A St,
le-treated mice of p < 0.0001***, except for Mono-A, which has a p < 0.0002***.
no-R, p = 0.004** (*p = 0.05–0.01, **p = 0.009–0.001, and ***p < 0.001).
(legend on next page)
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symbiotic cells importing and utilizing the lactate produced by
glycolysis (Kennedy et al., 2013; Sonveaux et al., 2008; Se-
menza, 2008). The concept of metabolic symbiosis in neoplasia
has been extended to interactions between cancer cells and
cancer-associated fibroblasts endothelial cells, macrophages
(Nakajima and Van Houten, 2013; and references therein), and
also documented in pancreatic adenocarcinoma (Guillaumond
et al., 2013). Its physiological basis lays in analogous symbiotic
relationships operative in certain normal tissues, in particular
brain and muscle (Draoui and Feron, 2011; and references
therein). The concept can now be extended further, with the
demonstrations that metabolic symbiosis can be induced in
response to a serious environmental stress—angiogenesis inhi-
bition, with consequent dropout and insufficiency of the tumor
vasculature, and widespread hypoxia—in models of pancreatic
neuroendocrine, breast, and renal cancer and in human RCC
(this report, and the accompanying reports by Pisarsky et al.
[2016] and Jime´nez-Valerio et al. [2016])
The question arises as to whether disruption of this mode of
resistance might have value in extending the duration of effica-
cious responses by anti-angiogenic therapies. We show that
metabolic symbiosis induced by sunitinib/axitinib can be disrup-
ted by concomitant inhibition of mTOR signaling, resulting in sig-
nificant reductions in TB and viability, but with only modest
(albeit significant) extension in survival. The limited survival
benefit suggests that ‘‘rapalogs’’ may not prove to be ideal drugs
to disrupt this form of adaptive resistance; moreover, combina-
tions of sunitinib/axitinib with the rapalog everolimus have
been tested clinically, with limited benefit and significant toxicity
(Molina et al., 2012). An alternative and potentially more attrac-
tive strategy may be to inhibit the MCT1 and/or MCT4 lactate
transporters with highly selective drugs. Indeed, the preliminary
studies reported herein and in the companion paper by Christo-
fori et al. (2016), in which expression of MCT4 was suppressed
genetically, encourages further preclinical and then potentially
clinical evaluation, given that a number of MCT1 and MCT4 in-
hibitors are in pharmacological development.
An important further consideration is that tumors faced with
vascular dropout and insufficiency evoked by potent AIs may
activate multiple modes of adaptive/evasive resistance, in
different regions of the tumor microenvironment. For example,
in the RIP1Tag2 mouse model of PanNET, sunitinib is apparently
inducing two distinctive modes of adaptive resistance, namely,
symbiosis in hypoxic regions of regressing tumors, and, as
reported previously, increased invasion and metastasis (Pa`ez-
Ribes et al., 2009), in part by upregulating cMET signaling
(Sennino et al., 2012). It is presently unclear whether these
invading cancer cells also induce symbiosis upon reaching a
size/location where diffusion of oxygen and glucose from co-Figure 6. mTOR Inhibition Disrupts Metabolic Symbiosis
(A) Evaluation by tissue immunostaining ofMCT1 (red) andMCT4 (green) expressio
combination (bottom row). The Mono-R-treated tumors (top left) appear similar t
expression of the MCT1/4 transporters. In the R+S-treated tumors (bottom), MC
which have expanded (red), in contrast, note relatively more expandedMCT4-pos
bar represents 100 mm. See also Figure S7.
(B) In contrast to the overlapping distribution between GLUT1 (red) and hypoxia (p
selectively upregulated in the non-hypoxic compartment of R+S-treated tumors
1156 Cell Reports 15, 1144–1160, May 10, 2016opted normal vessels is insufficient, evoking hypoxia and, in
turn, symbiosis. In fact, others have postulated that tumor acidity
may promote local invasion (Gatenby and Gillies, 2004; Estrella
et al., 2013). Interestingly, we observed that co-inhibiting angio-
genesis and mTOR reduces the incidence of metastasis, but it is
unclear whether this effect relates to disruption of symbiosis or
some other physiological parameter. Future studies in preclinical
and clinical trials may shed light on the interplay between
adaptive resistance mechanisms and means to concomitantly
disrupt them.
An interesting question, not fully answered by the current
studies, is how these metabolic clusters are induced to form,
and in particular, why the peri-vascular normoxic cancer cells
choose to take up and metabolize lactate and spare the limited
glucose for their hypoxic brethren. A plausible explanation for
the formation and disruption of metabolic symbiosis is illustrated
schematically in Figure 7, and might transpire as follows: exten-
sive vascular collapse elicited by the AIs results in hypoxia to
trigger the HIF1a transcription factor; HIF1a induces GLUT1
and MCT4 and activates glycolysis in the hypoxic cancer cells,
leading to high levels of lactate secretion; accumulating extracel-
lular lactate induces expression of the MCT1 lactate transporter
and, consequently, import of lactate into the normoxic cancer
cells; in concert with serum-derived glutamine, lactate is catab-
olized in the normoxic cancer cells with consequent induction of
mTOR signaling to promote tumor metabolism.
Notably, mTOR expression must be both cause and conse-
quence, since its pharmacological inhibition results in the nor-
moxic cancer cells upregulating a glucose transporter (GLUT2),
and apparently switching to secrete rather than import lactate,
resulting both in insufficient glucose for the hypoxic cells and
likely toxic acidosis in the extracellular microenvironment. In
addition, mTOR has been shown by others to be upregulated
by (Dura´n et al., 2012) and also to control glutamine metabolism
(Csibi et al., 2014). We extend these results by showing that its
inhibition blocks the conversion of lactate-derived pyruvate/
glutamate to alanine/a-ketoglutarate in R+S-treated tumors,
disrupting the production of TCA cycle intermediates, poten-
tially contributing to increased levels of (toxic and non-catabo-
lized) lactate. While plausible, this rationale for the assembly
and disruption of symbiosis will require future experimental
validation.
In conclusion, the induction of metabolic symbiosis in
response to vascular insufficiency elicited by potent AIs further
illustrates the remarkable propensity of cancer cells to circum-
vent barriers that arise during tumorigenesis, tumor progression,
and in response to treatment. This symbiotic adaptation
evidently constitutes another mechanism that enables tumors
to overcome the damaging effects of targeted therapies, byn in representative tumors treatedwithMono-R orMono-S (top row) or with the
o control vehicle-treated tumors (Figures 2F and S7) in having relatively weak
T4-expressing regions (green) are reduced versus MCT1-expressing regions,
itive regions in Mono-S-treated tumors (top: center and right: green). The scale
imo, green) in both Mono-S and R+S-treated tumors (top row), GLUT2 (red) is
(bottom row). The scale bars represent 25 mm. See also Figure S5B.
Figure 7. Schematic Conceptualizations of AI-Induced Metabolic Symbiosis
(A) Untreated PanNET tumors are highly vascularized and express low levels of MCT1, MCT4, and GLUT1, but appreciable levels of GLUT2. Potent AIs targeting
the VEGFR and PDGFR pathways elicit regression of the tumor vasculature with consequent regional hypoxia and tumor compartmentalization, marked by
upregulation of MCT4 and GLUT1 in a hypoxic compartment and elevated levels of MCT1 and pS6 along with reduced levels of GLUT2 in a normoxic
compartment. Combined inhibition of VEGFR/PDGFR andmTOR produces necrotic cell death in the hypoxic compartment, associated with GLUT2 upregulation
and altered lactate metabolism in the normoxic compartment, followed by eventual necrosis.
(B) Extensive vascular collapse resulting from AI treatment results in hypoxia that induces HIF1a, which in turn upregulates the glycolytic targets GLUT1 and
MCT4 in the hypoxic cancer cells, leading to high levels of lactate secretion. Accumulating extracellular lactate induces expression of theMCT1 at the cell surface
and lactate import into the normoxic compartment. In concert with serum-derived glutamine, lactate is catabolized in normoxic cancer cells with consequent
induction of mTOR signaling to promote tumor metabolism. The data imply that normoxic cancer cells spare glucose for the hypoxic cells and fuel themselves by
importing the lactate byproduct of glycolysis operative in the hypoxic cells in conjunction with glutamine. The bottom image suggests that metabolic symbiosis is
disrupted by inhibition of mTOR through (indirect) upregulation of GLUT2 in the normoxic cells within the putative symbiotic clusters. Additionally, NMR studies
indicate that mTOR inhibition disrupts the conversion of lactate-derived pyruvate/glutamate to alanine/a-ketoglutarate (anaplerosis) in dual-treated tumors,
thereby disrupting the production of TCA cycle intermediates and potentially further enhancing toxic lactate accumulation.
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co-opting cellular processes intended for important homeostatic
purposes that instead serve the evolving cancer.
EXPERIMENTAL PROCEDURES
Therapeutic Agents
Sunitinib and axitinib were purchased from LC laboratories. Rapamune (rapa-
mycin) was purchased from Galexis. Please see Supplemental Information for
details on dosing regimens, formulations, etc.
Mice
All mice used in this study were maintained in a pathogen-free barrier animal
facility of the Swiss Federal Institute of Technology Lausanne (EFPL) in accord
with Swiss regulations for the care and use of mice in experimental research.
3–13C-lactate and 1–13C-glucose in Tumor Cells
bTC3 cells were acclimated to ‘‘low’’ glucose (6.25 mM glucose + 4 mM
Gln +10% FCS). They were subsequently plated at 7 3 106 cells/10 cm tissue
culture dish in low glucose culture media for 2 days, switched to 0% glucose/
0% Gln + 10% FCS ON, then cultured in 20 mM 3–13C-lactate or 20 mM
1–13C-glucose + 4 mM Gln (no glucose) for 16 hr in hypoxic (1% O2/5% CO2)
or normoxic (21% O2/5% CO2) conditions, and harvested for NMR. Plates
were harvested individually on ice, rinsed twice with PBS, and collected in
0.9Mperchloric acid,whichwas subsequently titrated to approximately neutral
pH with 0.9 M potassium hydroxide (KOH); extracts were lyophilized for NMR.
3–13C-lactate Uptake in Tumors
Mice were treated for 10 days with sunitinib or vehicle control andwere infused
with 3–13-C-lactate in PBS, by intraperitoneal (i.p.) injection, over a period of
90 min. Pentobarbital was administered, and the mice were perfused
intravenously (i.v.) with a fluoresceinated lectin. Tumors were excised and
immediately quick frozen in liquid nitrogen. For NMR, the frozen tumors
were pulverized in liquid nitrogen, 0.9 M perchloric acid was added to the pul-
verized tumor tissue, rotated at 4C for 2 hr, and titrated with 0.9 M KOH to a
final of approximately pH 6–7.
NMR Acquisition
NMR analysis was performed using a Bruker AVII 800 MHz spectrometer
(18.8 T) equipped with a triple channel 5 mm cryoprobe (CPTCIz). 13C and
1H spectra were acquired using 30 angle pulses on 13C with decoupling on
proton (zgpg). A repetition delay (d1) of 3 s and 2,048 scans (ns) was used.
Spectra were processed with MestreNova software 10 using 5 Hz of line
broadening. The chemical shift scale was calibrated with 3–13C lactate
(21 ppm) as a reference, according to Shen et al. (1999) and Patel et al.
(2005). To prepare samples for introduction into the NMR, 300 ml of pulverized
cell solution was mixed with 100 ml of D2O (99.9% deuterated), shaken for
2 min, and directly poured into a 5 mm NMR tube.
Statistical Analysis
Statistical analysiswasperformedusingGraphPadPrism (GraphPadSoftware)
software, and a log rank test was performed using software from the Broad
Institute (http://bioinf.wehi.edu.au/software/russell/logrank/index.html). Due
to the small sample size (as few as eight animals per treatment group) and
the fact that not all the data are normally distributed, a non-parametric, suitable
Mann-Whitney testwas used (Figures 1A, 5B, 5C, S1A, S3A, S4B, andS4C; Ta-
bles S1 and S2), the log rank test was used for survival studies (Figure 5D), and
theStudent’s t testwas used for Figures 4C,S5C, andS5D. For the incidenceof
metastasis during survival trials (Figure S3B), data were analyzed using R,
where the event is ‘‘metastasis’’ and the horizontal axis is ‘‘age of sacrifice
due to declining health status’’, we tested whether the metastases are more
frequent in one group versus the other (function ‘‘survdiff’’).
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper is GEO:
GSE80436.1158 Cell Reports 15, 1144–1160, May 10, 2016SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.04.029.
AUTHOR CONTRIBUTIONS
E.A. and D.H. designed the study and wrote the manuscript. E.A. performed
the experiments and analyzed the data. P.M. produced and analyzed the
NMR data; C.M.W. analyzed/quantitated mTOR signaling in tumors; L.L. and
M.-W.P. produced the RNA-seq data; and M.-W.P. contributed to all aspects
of the preclinical studies and performed RT-qPCR experiments and ImageJ
analysis. S.S. performed bioinformatics analysis.
ACKNOWLEDGMENTS
We thank: J. Dessimov, G. Mancini, N. M€uller, and A. Hautier (HCF-EPFL) for
tissue sectioning, staining using the Ventana automated system, advice, and
assistance; G. Knott, M.-C. Croisier-Coeyteux, and S. Clerc-Rosset (BioEM-
EPFL) for TEM studies and discussions; J. Rougemont (BBF-EPFL) for statis-
tical analysis of metastasis; A. Piersigilli (PTEC-EPFL) for discussions on tumor
pathology; A. Barisic for NMR (ISIC-EPFL); and members of the Hanahan
laboratory, including E. Drori, B. Torchia, S. Andre´s, and P. Magliano for assis-
tance with animal trials and experimental work. We also thank R. Gatenby,
R. Gilles (Moffitt Cancer Center, Tampa, FL, USA), K. Schoonjans, K. Homi-
csko, S. Wullschleger, I. Michael, A. Santamaria-Martinez, J. Faget, U. Koch,
and N. Rigamonti (EPFL) for advice. Finally, we thank L. Ireula-Arispe (Univer-
sity of California, Los Angeles, CA, USA), G. Christofori (University of Basel,
Basel Switzerland), and M. de Palma (EPFL) for insightful comments on the
manuscript. This work was supported by an Advanced Grant from the Euro-
pean Research Council.
Received: August 6, 2015
Revised: January 28, 2016
Accepted: April 7, 2016
Published: April 28, 2016
REFERENCES
Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic
therapy. Nat. Rev. Cancer 8, 592–603.
Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. (1999). Ef-
fects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science
284, 808–812.
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D.
(2003). Benefits of targeting both pericytes and endothelial cells in the tumor
vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295.
Brugarolas, J., Lei, K., Hurley, R.L., Manning, B.D., Reiling, J.H., Hafen, E., Wit-
ters, L.A., Ellisen, L.W., and Kaelin, W.G., Jr. (2004). Regulation of mTOR func-
tion in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor
complex. Genes Dev. 18, 2893–2904.
Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. (2005). Drug resis-
tance by evasion of antiangiogenic targeting of VEGF signaling in late-stage
pancreatic islet tumors. Cancer Cell 8, 299–309.
Chiu, C.W., Nozawa, H., and Hanahan, D. (2010). Survival benefit with proap-
optotic molecular and pathologic responses from dual targeting of mammalian
target of rapamycin and epidermal growth factor receptor in a preclinical
model of pancreatic neuroendocrine carcinogenesis. J. Clin. Oncol. 28,
4425–4433.
Chun, M.G., Mao, J.H., Chiu, C.W., Balmain, A., and Hanahan, D. (2010). Poly-
morphic genetic control of tumor invasion in a mouse model of pancreatic
neuroendocrine carcinogenesis. Proc. Natl. Acad. Sci. USA 107, 17268–
17273.
Clarke, J.M., and Hurwitz, H.I. (2013). Understanding and targeting resistance
to anti-angiogenic therapies. J. Gastrointest. Oncol. 4, 253–263.
Cornu, M., Albert, V., and Hall, M.N. (2013). mTOR in aging, metabolism, and
cancer. Curr. Opin. Genet. Dev. 23, 53–62.
Csibi, A., Lee, G., Yoon, S.O., Tong, H., Ilter, D., Elia, I., Fendt, S.M., Roberts,
T.M., and Blenis, J. (2014). The mTORC1/S6K1 pathway regulates glutamine
metabolism through the eIF4B-dependent control of c-Myc translation. Curr.
Biol. 24, 2274–2280.
Draoui, N., and Feron, O. (2011). Lactate shuttles at a glance: from physiolog-
ical paradigms to anti-cancer treatments. Dis. Model. Mech. 4, 727–732.
Draoui, N., Schicke, O., Seront, E., Bouzin, C., Sonveaux, P., Riant, O., and
Feron, O. (2014). Antitumor activity of 7-aminocarboxycoumarin derivatives,
a new class of potent inhibitors of lactate influx but not efflux. Mol. Cancer
Ther. 13, 1410–1418.
Dura´n, R.V., Oppliger, W., Robitaille, A.M., Heiserich, L., Skendaj, R., Gottlieb,
E., and Hall, M.N. (2012). Glutaminolysis activates Rag-mTORC1 signaling.
Mol. Cell 47, 349–358.
Ebert, B.L., Firth, J.D., and Ratcliffe, P.J. (1995). Hypoxia and mitochondrial
inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting
sequences. J. Biol. Chem. 270, 29083–29089.
Ebos, J.M., and Kerbel, R.S. (2011). Antiangiogenic therapy: impact on inva-
sion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210–221.
Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G.,
and Kerbel, R.S. (2009). Accelerated metastasis after short-term treatment
with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239.
Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H.H., Ibrahim-Ha-
shim, A., Bailey, K., Balagurunathan, Y., Rothberg, J.M., Sloane, B.F., et al.
(2013). Acidity generated by the tumor microenvironment drives local invasion.
Cancer Res. 73, 1524–1535.
Folkman, J., Watson, K., Ingber, D., and Hanahan, D. (1989). Induction of
angiogenesis during the transition from hyperplasia to neoplasia. Nature
339, 58–61.
Gatenby, R.A., and Gillies, R.J. (2004). Why do cancers have high aerobic
glycolysis? Nat. Rev. Cancer 4, 891–899.
Guillam,M.T., H€ummler, E., Schaerer, E., Yeh, J.I., Birnbaum,M.J., Beermann,
F., Schmidt, A., De´riaz, N., and Thorens, B. (1997). Early diabetes and
abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat.
Genet. 17, 327–330.
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.N., Vidal, N., Bertheze`ne, P.,
Dusetti, N.J., Loncle, C., Calvo, E., Turrini, O., et al. (2013). Strengthened
glycolysis under hypoxia supports tumor symbiosis and hexosamine biosyn-
thesis in pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 110, 3919–
3924.
Gunnarsson, O., Pfanzelter, N.R., Cohen, R.B., and Keefe, S.M. (2015). Evalu-
ating the safety and efficacy of axitinib in the treatment of advanced renal cell
carcinoma. Cancer Manag. Res. 7, 65–73.
Jime´nez-Valerio, G., Martı´nez-Lozano, M., Bassani, N., Vidal, A., Ochoa-de-
Olza, M., Sua´rez, C., Garcı´a-del-Muro, X., Carles, J., Vin˜als, F., Graupera,
M., et al. (2016). Resistance to antiangiogenic therapies by metabolic symbio-
sis in renal cell carcinoma PDX models and patients. Cell Rep. 15, this issue,
1134–1143.
Kennedy, K.M., Scarbrough, P.M., Ribeiro, A., Richardson, R., Yuan, H., Son-
veaux, P., Landon, C.D., Chi, J.T., Pizzo, S., Schroeder, T., and Dewhirst, M.W.
(2013). Catabolism of exogenous lactate reveals it as a legitimate metabolic
substrate in breast cancer. PLoS ONE 8, e75154.
Lamonte, G., Tang, X., Chen, J.L., Wu, J., Ding, C.K., Keenan, M.M., Sango-
koya, C., Kung, H.N., Ilkayeva, O., Boros, L.G., et al. (2013). Acidosis induces
reprogramming of cellular metabolism to mitigate oxidative stress. Cancer
Metab. 1, 23.
Laplante, M., and Sabatini, D.M. (2012). mTOR signaling in growth control and
disease. Cell 149, 274–293.
Lu, K.V., and Bergers, G. (2013). Mechanisms of evasive resistance to anti-
VEGF therapy in glioblastoma. CNS Oncol. 2, 49–65.McIntyre, A., and Harris, A.L. (2015). Metabolic and hypoxic adaptation to anti-
angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 7,
368–379.
Molina, A.M., Feldman, D.R., Voss, M.H., Ginsberg, M.S., Baum,M.S., Brocks,
D.R., Fischer, P.M., Trinos, M.J., Patil, S., andMotzer, R.J. (2012). Phase 1 trial
of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Cancer 118, 1868–1876.
Nakajima, E.C., and Van Houten, B. (2013). Metabolic symbiosis in cancer:
refocusing the Warburg lens. Mol. Carcinog. 52, 329–337.
Nolan-Stevaux, O., Truitt, M.C., Pahler, J.C., Olson, P., Guinto, C., Lee, D.C.,
and Hanahan, D. (2010). Differential contribution to neuroendocrine tumori-
genesis of parallel egfr signaling in cancer cells and pericytes. Genes Cancer
1, 125–141.
Pa`ez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vin˜als, F., In-
oue, M., Bergers, G., Hanahan, D., and Casanovas, O. (2009). Antiangiogenic
therapy elicits malignant progression of tumors to increased local invasion and
distant metastasis. Cancer Cell 15, 220–231.
Patel, A.B., de Graaf, R.A., Mason, G.F., Rothman, D.L., Shulman, R.G., and
Behar, K.L. (2005). The contribution of GABA to glutamate/glutamine cycling
and energy metabolism in the rat cortex in vivo. Proc. Natl. Acad. Sci. USA
102, 5588–5593.
Pe´rez-Escuredo, J., Dadhich, R.K., Dhup, S., Cacace, A., Van He´e, V.F., De
Saedeleer, C.J., Sboarina, M., Rodriguez, F., Fontenille, M.J., Brisson, L.,
et al. (2016). Lactate promotes glutamine uptake and metabolism in oxidative
cancer cells. Cell Cycle 15, 72–83.
Pisarsky, L., Bill, R., Fagiani, E., Dimeloe, S., Goosen, R.W., Hagmann, J.,
Hess, C., and Christofori, G. (2016). Targeting metabolic symbiosis to over-
come resistance to anti-angiogenic therapy. Cell Rep. 15, this issue, 1161–
1174.
Raymond, E., Dahan, L., Raoul, J.L., Bang, Y.J., Borbath, I., Lombard-Bohas,
C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011). Sunitinib malate for
the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364,
501–513.
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C.C., and
De Palma, M. (2014). Role of angiopoietin-2 in adaptive tumor resistance to
VEGF signaling blockade. Cell Rep. 8, 696–706.
Rivera, L.B., Meyronet, D., Hervieu, V., Frederick, M.J., Bergsland, E., and
Bergers, G. (2015). Intratumoral myeloid cells regulate responsiveness and
resistance to antiangiogenic therapy. Cell Rep. 11, 577–591.
Seagroves, T.N., Ryan, H.E., Lu, H., Wouters, B.G., Knapp, M., Thibault, P.,
Laderoute, K., and Johnson, R.S. (2001). Transcription factor HIF-1 is a neces-
sary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. 21,
3436–3444.
Semenza, G.L. (2008). Tumor metabolism: cancer cells give and take lactate.
J. Clin. Invest. 118, 3835–3837.
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R.M., Williamson, C.W.,
Bhagwandin, V., Tabruyn, S.P., You, W.K., Chapman, H.A., Christensen,
J.G., et al. (2012). Suppression of tumor invasion andmetastasis by concurrent
inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
Cancer Discov. 2, 270–287.
Shen, J., Petersen, K.F., Behar, K.L., Brown, P., Nixon, T.W., Mason, G.F.,
Petroff, O.A., Shulman, G.I., Shulman, R.G., and Rothman, D.L. (1999). Deter-
mination of the rate of the glutamate/glutamine cycle in the human brain by
in vivo 13C NMR. Proc. Natl. Acad. Sci. USA 96, 8235–8240.
Shojaei, F., and Ferrara, N. (2008). Role of the microenvironment in tumor
growth and in refractoriness/resistance to anti-angiogenic therapies. Drug
Resist. Updat. 11, 219–230.
Sonveaux, P., Ve´gran, F., Schroeder, T., Wergin, M.C., Verrax, J., Rabbani,
Z.N., De Saedeleer, C.J., Kennedy, K.M., Diepart, C., Jordan, B.F., et al.
(2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells
in mice. J. Clin. Invest. 118, 3930–3942.
Ulanet, D.B., Ludwig, D.L., Kahn, C.R., and Hanahan, D. (2010). Insulin recep-
tor functionally enhances multistage tumor progression and conveys intrinsicCell Reports 15, 1144–1160, May 10, 2016 1159
resistance to IGF-1R targeted therapy. Proc. Natl. Acad. Sci. USA 107, 10791–
10798.
Ullah, M.S., Davies, A.J., and Halestrap, A.P. (2006). The plasma membrane
lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through
a HIF-1alpha-dependent mechanism. J. Biol. Chem. 281, 9030–9037.
Vasudev, N.S., and Reynolds, A.R. (2014). Anti-angiogenic therapy for cancer:
current progress, unresolved questions and future directions. Angiogenesis
17, 471–494.
Waagepetersen, H.S., Bakken, I.J., Larsson, O.M., Sonnewald, U., and
Schousboe, A. (1998). Metabolism of lactate in cultured GABAergic neurons
studied by 13C nuclear magnetic resonance spectroscopy. J. Cereb. Blood
Flow Metab. 18, 109–117.1160 Cell Reports 15, 1144–1160, May 10, 2016Welti, J., Loges, S., Dimmeler, S., and Carmeliet, P. (2013). Recent molecular
discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin.
Invest. 123, 3190–3200.
Yang, C., Harrison, C., Jin, E.S., Chuang, D.T., Sherry, A.D., Malloy, C.R., Mer-
ritt, M.E., and DeBerardinis, R.J. (2014). Simultaneous steady-state and
dynamic 13C NMR can differentiate alternative routes of pyruvate metabolism
in living cancer cells. J. Biol. Chem. 289, 6212–6224.
Yao, J.C., Shah, M.H., Ito, T., Bohas, C.L., Wolin, E.M., Van Cutsem, E., Hob-
day, T.J., Okusaka, T., Capdevila, J., de Vries, E.G., et al.; RAD001 in
Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
(2011). Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl.
J. Med. 364, 514–523.
